Intraparenchymal Neural Stem/Progenitor Cell Transplantation for Ischemic Stroke Animals: A Meta-Analysis and Systematic Review

Table 3

Subgroup meta-analysis and metaregression of variants correlated with infarct volume reduction.

Clinical variants	Effect size (95% CI)	, value	df	Univariate analysis (, )
Administration time poststroke				26.92%, 0.008
≤24 h	1.57 (1.03–2.21)	58.3%, 0.008	10
1–7 d	1.64 (1.11–2.16)	0.0%, 0.496	5
≥7 d	0.44 (−0.17–1.04)	81.8%, ≤0.001	10
Cell dosage				1.27%, 0.261
≤1 × 10^6 cells/kg	1.45 (0.99–1.91)	57.4%, 0.012	9
1–5 × 10^6 cells/kg	0.82 (0.06–1.59)	83.1%, ≤0.001	10
>5 × 10^6 cells/kg	0.99 (0.25–1.73)	61.5%, 0.016	6
Animal model				0.79%, 0.280
Transient	1.24 (0.82–1.67)	68.9%, ≤0.001	19
Permanent	0.78 (−0.07–1.64)	82.7%, ≤0.001	7
Graft sites
Global	0.24 (−0.59–1.08)	40.1%, 0.196	1	2.06%, 0.201
Focal	1.19 (0.78–1.60)	75.2%, ≤0.001	25
Cell donor species				20.00%, 0.025
Mouse	1.46 (0.84–2.08)	54.7%, 0.031	7
Rat	1.73 (1.15–2.31)	45.7%, 0.075	7
Human	0.51 (−0.08–1.10)	81.0%, ≤0.001	11
Cell recipient species				−4.82%, 0.761
Mouse	0.98 (0.40–1.56)	31.2%, 0.201	5
Rat	1.12 (0.64–1.60)	79.8%, ≤0.001	20
Others	1.61 (0.35–2.87)		0
Immunoreactivity				15.24%, 0.044
No	1.52 (1.11–1.93)	30.9%, 0.136	12
Yes	0.76 (0.21–1.31)	82.1%, ≤0.001	14
State of donor cells				5.14%, 0.115
PSC-NSPCs	0.63 (−0.13–1.38)	84.1%, ≤0.001	7
WT-NSPCs	1.33 (0.88–1.78)	68.2%, ≤0.001	19
Immunosuppression drugs				−3.64%, 0.657
No	1.17 (0.22–2.12)	78.6%, ≤0.001	6
Yes	0.95 (0.32–1.58)	83.2%, ≤0.001	11
Unknown	1.28 (0.82–1.74)	26.9%, 0.205	8
Blinding				−5.59%, 0.758
No	1.32 (0.17–2.46)	85.8%, ≤0.001	6
Yes	1.06 (0.67–1.46)	69.1%, ≤0.001	20
Randomization				−3.47%, 0.483
No	1.33 (0.61–2.05)	77.1%, ≤0.001	10
Yes	0.99 (0.53–1.46)	74.6%, ≤0.001	16